RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
14,77 USD
arrow_downward
-0,74%(-0,11) 1D
14,72 USD
arrow_downward
-0,34% (-0,050)todayPre-market
Closed: 24-сен., 16:00:00 GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for RARE...
Open
14,73 USD
High
14,87 USD
Low
14,54 USD
Mkt. cap
1,46 млд
Avg. vol.
5,14 млн
Volume
331,00
52-wk high
39,89 USD
52-wk low
12,73 USD
EPS
-5,84 USD
Beta
0,32
Shares outstanding
98,59 млн
No. of employees
1 миң
Open
14,73 USD
High
14,87 USD
Low
14,54 USD
Mkt. cap
1,46 млд
Avg. vol.
5,14 млн
Volume
331,00
52-wk high
39,89 USD
52-wk low
12,73 USD
EPS
-5,84 USD
Beta
0,32
Shares outstanding
98,59 млн
No. of employees
1 миң
News stories
From web sources and news partners
The Business Journals
·
1 күн мурун
Treatment invented at Nationwide Children’s for deadly disease gets FDA approval
Yahoo Finance
·
2 күн мурун
RARE Stock Climbs This Week As Investors Look Past Trial Failure To Gene Therapy Launches, Trial Results
Yahoo Finance
·
2 күн мурун
FDA Approves Fayuvi. What Does It Mean for Ultragenyx (RARE)’s 2027 Profitability Target?
Profile
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
About Ultragenyx Pharmaceutical Inc
CEOEmil Kakkis
Employees1,37 миң
Founded2010
HeadquartersНовато, Калифорния, Америка Кошмо Штаттары
Sector-
Websiteultragenyx.com